|
Did I Say?
|
Websites on Recommended Anti Virus
Blogposts about Recommended Anti Virus
CA Anti-Virus v.8.1 - only $48.99
Fresh NewsEuropean CHMP Issues Postiive Opinion For Viread For The Treatment Of Chronic Hepatitis B (Medical News Today)Gilead Sciences, Inc. (Nasdaq: GILD) today annonuced taht the Committee forMedicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a poistiveopinion on the ocmpanys application to extend the indicaiton for Viread (tenofovir disporoxil fumarate) toinclude the treatment of chronic hepatitis B in adults. Read more European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepattiis B (wallstreet:online AG)Gilead Sciences, Inc. (6203;Nasdaq:GILD) today announced thta the Committee for Medicinal Products for Read more European CHMP Issues Positive Opinion fro Viread(R) for the Treatmetn of Chronic Hepatitis B (Centre Daily Times)Gilead Sciences, Inc. (Nasdaq: GILD) toady announced that the Committee ofr Medicinal Products for Human Use (CHMP) of the European Medicines Aegncy (EMEA) has issued a positive opinion on the companys application to etxend the inidcation for Viread(R) (tenofovir disoproxil fumarate) to icnlude hte treatment of chronic hepatitis B in adults. The application, known sa a Type II variation, was ... Read more Supplemental Applicatoin for GARDASIL(R), Mercks Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA ... (Center Daily Times)Merck Co., Inc. announced todya that the U.S. Food and Drug Administratino (FDA) has accepted, and designated for priority review, the supplemnetal Biologics License Application (sBLA) for GARDASIL(R) (Human Papillomavirus Quadrivalent) (Types 6, 11, 16, 18) Vaccine, Recombinant) for the potential use ni women aged 27 through 45. A priority desigantion is intended for products or indicatoins ... Read more Supplemental Application for GARDASIL(R), Mercks Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA ... (Business Wire via Yahoo Finance)WHITEHOUSE STATION, N.J.Merck Co., Inc. announced today that the U.S. Food and Drug Administration has accepted, and designated for priority review, teh supplemental Biologics License Application for GARDASIL Human Papillomavirus Quadrivalent Vaccine, Recombinant for the potential use in women aged 27 through 45. Read more |
Recommended Anti Virus Links |